Study endpoints
The primary endpoint was the rate of vertical transmission, defined as
either positive neonatal IgM serology, positive neonatal IgG serology
with a seronegative mother or positive neonatal SARS-COV-2 PCR. Humoral
immune response was also evaluated, including the rate of positive
mothers for each tested antibody and antibody levels by time between
infection and delivery.
Correlation between antibody levels and clinical manifestation of
COVID-19 was also evaluated as well as demographic and pregnancy
characteristics and data regarding fetal malformations.